About
Pulmocide Ltd develops novel inhaled medicines, including the investigational drug opelconazole, targeting difficult-to-treat respiratory diseases such as invasive pulmonary aspergillosis and other Aspergillus-associated conditions.
Explore Pulmocide Ltd's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.